PRP Concepts

What PRP Concepts does

PRP Concepts, Inc. is a privately-held, New Jersey-domiciled medical device company commercializing the CASCADE® Autologous Platelet System, a single-use, FDA-approved, point-of-care kit that prepares Platelet Rich Fibrin Matrix (PRFM) from a patient's own blood for chronic wound healing. The technology uses a proprietary gel-based two-tube centrifugation process to isolate high-purity platelet-rich plasma and form a solid fibrin membrane that delivers sustained growth factor release over 7–10 days, without exogenous thrombin and with a leukocyte-poor formulation. The kit is sold to podiatrists, wound care specialists, hospitals, and medical centers that treat chronic non-healing wounds, including diabetic foot ulcers and venous leg ulcers; the company also supports a self-pay patient channel at participating clinics.

The company monetizes through one-time sales of disposable CASCADE kits to healthcare providers, with go-to-market executed via a sales-led, field-based model anchored by Client Product Specialists, KOL onboarding, and clinical instructor programs at institutions such as Jersey Shore University Medical Center. Documented clinical outcomes include 64.7% closure of venous leg ulcers within 16 weeks, 100% healing in 86% of VA patients aged 58–78, and significantly higher odds of complete closure versus control across ulcer etiologies. The operating stack is consultant-heavy: regulatory work is handled by MCRA, securities counsel by Reitler Kailas & Rosenblatt, financial leadership by Bridge CFO Services, and biostatistics by Biostatistical Consulting Inc., which is consistent with an early-stage commercialization posture. The company is currently raising capital through a 2026 Private Placement Memorandum.

Name

PRP Concepts

Legal name

PRP Concepts, Inc

Website

https://prpconcepts.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

PRP Concepts, Inc. is a New Jersey-based medical device company that sells the FDA-approved CASCADE® Autologous Platelet System, a single-use kit that prepares platelet-rich fibrin matrix at the point of care for healthcare providers treating chronic wounds such as diabetic foot ulcers and venous leg ulcers.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin) (HLAIAHAG)

Keywords

• Wound care devices
• Platelet rich fibrin
• Autologous platelet system
• Diabetic foot ulcer treatment
• Regenerative medicine

Headquarters

HQ city

Middletown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations

Revenue model

1. CASCADE Kit Sales: Sale of single-use, disposable CASCADE Autologous Platelet System kits to healthcare providers for point-of-care wound treatment. Medical device sold to hospitals, wound care clinics, and podiatry practices.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

PRP Concepts manufactures and sells the CASCADE Autologous Platelet System, a single-use disposable medical device kit designed for point-of-care preparation of Platelet Rich Fibrin Matrix (PRFM) from a patient's own blood. The proprietary two-tube system produces a solid fibrin membrane delivering sustained growth factor release over 7-10 days for chronic wound healing, particularly diabetic foot ulcers and venous leg ulcers.

Product overview

PRP Concepts offers a single unified product: the CASCADE® Autologous Platelet System, which is a complete single-use, disposable kit for preparing Platelet Rich Fibrin Membrane (PRFM) at the point of care. The system includes specialized tubes, a proprietary gel for PRP isolation, and a PRFM formation bottle. The CASCADE® PRFM kit produces a 210-fold higher concentration of platelets compared to whole blood and provides sustained growth factor release for wound healing applications, particularly for diabetic foot ulcers and venous leg ulcers. The kit components include tourniquet, butterfly needle, tube holder, 2 PRP isolation tubes, PRP transfer device, and PRFM formation bottle (centrifuge not included).

Differentiator

Problem solved

Functional benefit

Brands

• CASCADE®: The CASCADE® Autologous Platelet System is a single-use, disposable kit designed for point-of-care preparation of Platelet Rich Fibrin Matrix (PRFM) for wound healing applications.

Products and services

• CASCADE Autologous Platelet System

Quantifiable outcome

• 64.7% of VLUs closed within 16 weeks with average of 2 applications per patient
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• MCRA (McGlynn, Clark & Rapp, LLC)coreImplementation/ SI/ Consulting PartnerMCRA Regulatory Affairs provides regulatory consultancy services with expertise in biologics, cell therapies, and medical devices. Chief consultant has 9 years regulatory affairs experience including 8 years at FDA overseeing biologics and cell therapies, serving as CBER Lead for Cell Therapies and Devices and CDRH Lead for Spinal and Orthopedic Devices.
• Reitler Kailas & RosenblattcoreImplementation/ SI/ Consulting PartnerGregory Petroff serves as Lead Securities Counsel, bringing extensive experience advising businesses from startup to acquisition, overseeing $1.3 billion+ in corporate transactions. Expertise in Corporate Law, M&A, Securities Compliance, Private Equity, and Venture Capital.
• Bridge CFO ServicescoreImplementation/ SI/ Consulting PartnerMichele Kothe founded Bridge CFO Services, providing financial leadership to venture-backed technology and healthcare companies. Has helped companies raise more than $100 million in dilutive and non-dilutive funding.
• Two Rivers Tax & Accounting ServiceminorImplementation/ SI/ Consulting PartnerBrian Camp serves as Partner & CPA, specializing in tax preparation, financial reporting, tax compliance, planning, and financial management for start-up companies.
• Biostatistical Consulting Inc. (BCI)coreImplementation/ SI/ Consulting PartnerDr. Eugene C. Poggio founded BCI specializing in clinical trial design and analysis since 2007. Provides 40+ years of biostatistics experience for pharmaceuticals, biotechnology, and medical devices ensuring regulatory approvals and data integrity.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Arthrex: Arthrex is a major orthopedic and sports medicine medical device company with the Arthrex ACP (Autologous Conditioned Plasma) double-syringe PRP system. Although its core focus is orthopedics, it overlaps with PRP Concepts in PRP technology, customer overlap (surgeons, podiatrists), and regenerative medicine positioning.
• MiMedx Group: MiMedx is a publicly-traded regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) into the same chronic wound care market — diabetic foot ulcers and venous leg ulcers — competing for the same podiatry and wound clinic budgets.
• Zimmer Biomet: Zimmer Biomet offers the GPS III Platelet Concentration System in orthopedics and sports medicine, an autologous blood-derived PRP product that overlaps with CASCADE's underlying technology and provider base, though focused primarily on orthopedic indications.
• Smith+Nephew: Smith+Nephew is a global wound care major offering NPWT, advanced dressings, and skin substitutes (PICO, ALLEVYN) into the same wound care provider accounts as PRP Concepts, with overlapping patient populations (DFU, VLU, chronic wounds).
• Convatec: Convatec is a global wound care and ostomy leader with advanced dressings and the InnovaMatrix wound matrix, serving the same diabetic foot ulcer and venous leg ulcer patient populations in podiatry and wound care clinics.
• Terumo BCT: Terumo BCT is a global leader in blood component processing, including platelet-rich plasma collection and processing systems. Its Reveos and centrifugal platforms compete in the institutional blood-processing and regenerative medicine space adjacent to CASCADE's autologous blood processing niche.
• Coloplast: Coloplast operates a major Wound Care business (Biatain, Comfeel portfolios) supplying standard wound dressings and skin substitutes for DFUs and VLUs in the same hospital and outpatient wound clinic channels.
• Organogenesis Holdings: Organogenesis is a publicly-traded regenerative medicine company offering skin substitutes (Apligraf, Dermagraft) for chronic wounds, competing head-to-head with autologous PRP approaches like CASCADE for DFU and VLU indications.

Direct peers

• Emcyte Corporation: Emcyte is a direct competitor in point-of-care PRP/PRF preparation kits for regenerative medicine and wound care, selling the PurePRP and Concentrated Growth Factor systems to the same podiatry, wound care, and orthopedic provider base as CASCADE.

Emerging players

• Royal Biologics: Royal Biologics is an emerging regenerative medicine company offering bone marrow aspirate and PRP kits for orthopedic and wound care use, with significant partial overlap in point-of-care autologous blood processing analogous to CASCADE's PRFM system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRP Concepts